Jade Biosciences, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Jade Biosciences, Inc. (JBIO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $773.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-06.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-10
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $0.00.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $773.00K, a 275.24% increase year-over-year.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $773.00K, a 275.24% increase from fiscal 2024.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $206.00K.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $765.00K, a 41.14% increase from fiscal 2021.
- Jade Biosciences, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $542.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $0.00 derived: sum of 2 quarters · filed 2026-03-06 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $773.00K 10-K · filed 2026-03-06 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $773.00K 10-Q · filed 2025-11-14 | $773.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $773.00K 10-Q · filed 2026-08-10 | $773.00K derived: sum of 3 quarters · filed 2026-08-10 | $773.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $773.00K 10-Q · filed 2026-05-07 | $773.00K derived: sum of 2 quarters · filed 2026-05-07 | $773.00K derived: sum of 3 quarters · filed 2026-05-07 | $773.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $206.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $206.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $206.00K 10-Q · filed 2024-08-12 | ||
| 2024-03-31 | $206.00K 10-Q · filed 2025-04-25 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $0.00 derived: sum of 2 quarters · filed 2024-03-25 | $765.00K 10-K · filed 2024-03-25 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $765.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $765.00K 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $542.00K 10-K · filed 2023-03-29 | ||
| 2021-09-30 | $583.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |